- The European Commission approves Pharmacyclics (NASDAQ:PCYC) and Janssen's (JNJ) Imbruvica (ibrutinib) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma or adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy or in first-line CLL patients in the presence of 17p deletion or TP53 mutation who are unsuitable for chemotherapy.
- The FDA approved Imbuvica in July.